Heron Therapeutics Inc (NASDAQ: HRTX) is 5.88% higher on its value in year-to-date trading and has touched a low of $0.50 and a high of $3.93 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The HRTX stock was last observed hovering at around $1.78 in the last trading session, with the day’s gains setting it 0.02%.
Currently trading at $1.80, the stock is -5.61% and -5.35% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.4 million and changing 1.12% at the moment leaves the stock -31.11% off its SMA200. HRTX registered 199.20% gain for a year compared to 6-month loss of -32.08%. The firm has a 50-day simple moving average (SMA 50) of $1.9018 and a 200-day simple moving average (SMA200) of $2.61295.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -8.16% gain in the last 1 month and extending the period to 3 months gives it a -41.94%, and is -3.74% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.28% over the week and 7.15% over the month.
Heron Therapeutics Inc (HRTX) has around 126 employees, a market worth around $273.01M and $136.36M in sales. Profit margin for the company is -35.29%. Distance from 52-week low is 260.00% and -54.20% from its 52-week high. The company has generated returns on investments over the last 12 months (-34.98%).
Heron Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -0.03 with sales reaching $36.62M over the same period.The EPS is expected to grow by 84.19% this year, but quarterly earnings will post 16.10% year-over-year. Quarterly sales are estimated to grow 16.50% in year-over-year returns.
227.0 institutions hold shares in Heron Therapeutics Inc (HRTX), with institutional investors hold 87.29% of the company’s shares. The shares outstanding are 150.29M, and float is at 144.09M with Short Float at 22.00%. Institutions hold 86.69% of the Float.
The top institutional shareholder in the company is RUBRIC CAPITAL MANAGEMENT LP with over 26.71 million shares valued at $93.5 million. The investor’s holdings represent 17.6678 of the HRTX Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 8.62 million shares valued at $30.16 million to account for 5.6984 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 8.33 million shares representing 5.5062 and valued at over $29.14 million, while ADAGE CAPITAL PARTNERS GP, L.L.C. holds 5.0265 of the shares totaling 7.6 million with a market value of $26.6 million.
Heron Therapeutics Inc (HRTX) Insider Activity
The most recent transaction is an insider purchase by Forbes William P, the company’s EVP, Chief Development Officer. SEC filings show that Forbes William P bought 25,000 shares of the company’s common stock on Nov 17 ’23 at a price of $1.09 per share for a total of $27250.0. Following the purchase, the insider now owns 79000.0 shares.
Heron Therapeutics Inc disclosed in a document filed with the SEC on Nov 16 ’23 that Forbes William P (EVP, Chief Development Officer) bought a total of 50,000 shares of the company’s common stock. The trade occurred on Nov 16 ’23 and was made at $0.94 per share for $46995.0. Following the transaction, the insider now directly holds 54000.0 shares of the HRTX stock.
Still, SEC filings show that on Nov 16 ’23, Collard Craig A (Chief Executive Officer) acquired 150,000 shares at an average price of $0.92 for $0.14 million. The insider now directly holds 186,496 shares of Heron Therapeutics Inc (HRTX).
